Get startedLog in
    Picture of Kymera Therapeutics logo

    KYMR — Kymera Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

    Picture of Kymera Therapeutics logoKymera Therapeutics
    09/04/2026 12:15
    April 9 (Reuters) - Kymera Therapeutics Inc KYMR.O:

KYMERA THERAPEUTICS ANNOUNCES GILEAD SCIENCES’ OPTION EXERCISE TO LICENSE KT-200, ORAL CDK2 MOLECULAR GLUE DEGRADER DEVELOPMENT CANDIDATE

KYMERA THERAPEUTICS INC - TO RECEIVE $45 MILLION MILESTONE PAYMENT FROM GILEAD FOR KT-200 OPTION

KYMERA THERAPEUTICS INC - ELIGIBLE FOR UP TO $750 MILLION IN TOTAL PAYMENTS UNDER AGREEMENT

KYMERA THERAPEUTICS INC - HAS REALIZED $85 MILLION IN UPFRONT AND OPTION PAYMENTS TO DATE

KYMERA THERAPEUTICS INC - MAY RECEIVE TIERED ROYALTIES FROM HIGH SINGLE-DIGIT TO MID-TEENS ON SALES

KYMERA THERAPEUTICS INC - GILEAD TO ADVANCE KT-200 INTO IND-ENABLING STUDIES FOR 2027 IND FILING

Source text: ID:nGNX7PkM4m

Further company coverage: KYMR.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kymera Therapeutics

    See all news